Full List Of Stories
ReNeuron soars after partnering with Chinese pharma giant
ReNeuron's shares soared on Tuesday after it signed an exclusive licence agreement with Shanghai Fosun Pharmaceutical Industrial Development (SFPID) for the development, manufacture and commercialisation of ReNeuron's cell therapy programmes in China.
FTSE 250 movers: Housebuilders crumble, Sirius soars
London's FTSE 250 index was 0. 34% lower at 19,449. 99 in afternoon trade on Tuesday, as housebuilders and construction outfits pulled the index lower amid continued Brexit confusion.
Comptoir swings to loss as costs bite
Comptoir Group on Tuesday swung to an annual loss as a jump in revenue was offset by increased costs as the company warned of "unprecedented political and general uncertainty".
Avacta falls as stuttering revenues exacerbate losses
Avacta Group's shares slid on Tuesday as interim revenues dropped on the back of a lower contribution from the life sciences division, which resulted in wider losses.
Anexo beats market expectations as revenues leap
Anexo Group's shares climbed on Tuesday as it reported that annual revenues soared, but profit before tax remained largely flat as cost of sales and administrative expenses moved higher in tandem.
Societe Generale to cut 1,600 jobs to restore profitability
French banking giant Societe Generale on Tuesday revealed plans to shed 1,600 positions following its latest operational review, starting from the third quarter of 2019 onwards.
Destiny Pharma 'well funded' despite wider loss
Destiny Pharma on Tuesday reported a wider annual loss as it increased research and development costs, although the company is "well funded" through to the second half of next year.